This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Fructose-bisphosphate aldolase C.
Human | |
---|---|
Gene Name: | ALDOC |
Uniprot: | P09972 |
Entrez: | 230 |
Belongs to: |
---|
class I fructose-bisphosphate aldolase family |
ALDC; aldolase 3; aldolase C, fructose-bisphosphate; Brain-type aldolase; EC 4.1.2.13; fructoaldolase C; fructose-1,6-biphosphate triosephosphate lyase; fructose-bisphosphate aldolase C
Mass (kDA):
39.456 kDA
Human | |
---|---|
Location: | 17q11.2 |
Sequence: | 17; NC_000017.11 (28573115..28576963, complement) |
When you're preparing your experiments for immunoblotting with boster proteins, you might be interested in the use of anti-Aldolase C N-terminal specific monoclonal antibody. This article will cover the use of this marker in immunoblotting, gene infographics, and Immunoblotting with boster proteins. Read on to learn more. Boster Bio: Best Uses of the ALDOC Marker
Aldolases are glycolytic cytosolic enzymes that catalyze the conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate. They are coded by three distinct genes in mammals, aldolase A, aldolase B, and aldolase C. Aldolase C is expressed specifically in the brain and is a marker for astrocytes. Antibodies against aldolase C can also be used to detect overexpression of aldolase C in cancerous tissues and cells.
The antibody was diluted using PBST and a dilution of 3% BSA/PBST. After incubating, the membrane was washed with a PBS buffer, a secondary anti-rabbit antibody, and horseradish peroxidase. The samples were analyzed by immunohistochemistry using the secondary anti-rabbit antibody and the control immunoglobulin.
Several studies have shown the anti-Aldolase C antibody has important implications for pineal research. According to a study published in J. Pineal Res., Boster's anti-Aldolase C: N-terminal specific monoclonal antibody is an effective tool to detect toxins in pineal tissues and hepatocytes.
The therapeutic antibodies targeting COVID-19 may provide relief from CSS in patients with severe COVID-19. Despite these challenges, therapeutic antibodies for COVID-19 are currently in clinical trials. The clinical trial results of these antibodies indicate they could be effective in the treatment of COVID-19 in patients with CSS. However, if they are not, it will be a long way until the drugs are approved for wider use.
A recent study has shown that an immunoglobulin fragment derived from a SARS-CoV-2 patient is an effective neutralizing mAb. Its IC50 value of 0.03 mg/ml was remarkably low, indicating its potential to neutralize a pseudovirus. It competes with ACE2 for binding sites. Despite having a low IC50 value, CV30 is highly specific and potent, with minimal somatic mutations. Furthermore, it competes with ACE2 for binding sites in the RBD.
Western Blotting, or immunoblotting, is a technique for identifying individual proteins from protein mixtures. The proteins are separated on a gel by charge, size, and other differences. The bands are then transferred onto a carrier membrane, such as nitrocellulose or PVDF. The target protein is then readily accessible for antibody binding. Western Blotting is widely used in research and diagnostic applications. It is an excellent method for determining protein abundance, relative molecular weight, and protein distribution.
The process of immunoblotting involves applying the primary and secondary antibodies to a membrane. The primary antibody binds to the target protein and the secondary antibodies bind to the other protein, which then recognizes the label antibody. The primary antibody may be biotin-conjugated, or be a colour or radioactive antibody. After applying the primary antibodies, the membrane is washed using a detergent-based buffer.
PVDF membranes are prepared for immunoblotting. The membranes are fixed with 5% bovine serum albumin and 0.05% Tween-20. Primary antibodies were then probed with lectins or TBST. After the PVDF membranes had been fixed, the immunoreactive bands were detected using an XRS image system, manufactured by Bio-Rad Laboratories. If you are looking for a reliable way to determine which proteins are present on a PVDF membrane, immunoblotting can help you to make the right decision.
In immunoblotting with boster proteins, antibodies are raised against synthetic peptide antigens that resemble the posttranslational modifications that proteins go through in vivo. The antibodies bind to these modifications and identify them in protein blots. The method used to identify these modifications is more sensitive than the method used for the detection of specific proteins in cells. But the main difference between the two methods lies in the fact that the method uses more than one protein.
The ALDOC Marker is a protein that is induced by TBI and SCI. It is also known as BLBP or aB-crystallin. ALDOC is a trauma-specific proteolytic cleavage product that can be used in predictive assays of drug response in cancer cells. The ALDOC marker has many potential uses, including the early diagnosis of cancer and monitoring tumor growth.
PMID: 3105602 by Rottmann W.H., et al. The complete amino acid sequence of the human aldolase C isozyme derived from genomic clones.
PMID: 3267224 by Buono P., et al. The complete nucleotide sequence of the gene coding for the human aldolase C.